{"id":70528,"date":"2026-07-23T22:17:21","date_gmt":"2026-07-23T14:17:21","guid":{"rendered":"https:\/\/flcube.com\/?p=70528"},"modified":"2026-07-23T22:17:23","modified_gmt":"2026-07-23T14:17:23","slug":"cspc-pharmaceutical-launches-phase-2-trial-of-sys-6026-mrna-vaccine-for-hpv-related-cervical-precancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70528","title":{"rendered":"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced the initiation of a <strong>Phase 2 clinical trial<\/strong> in China for <strong>SYS 6026 injection<\/strong>, a <strong>therapeutic mRNA vaccine<\/strong> targeting <strong>human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL)<\/strong>. The Class 1 therapeutic biological product represents China&#8217;s first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group Ltd (HKG: 1093)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>SYS 6026 injection<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class 1 therapeutic biological product<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase 2<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HPV 16\/18-related cervical HSIL<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Clinical trial initiated July 23, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-architecture\" class=\"wp-block-heading\">Molecular Architecture<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform<\/strong>: Therapeutic mRNA vaccine delivered via lipid nanoparticles (LNP)<\/li>\n\n\n\n<li><strong>Targets<\/strong>: E6 and E7 oncoprotein antigens of HPV subtypes 16 and 18<\/li>\n\n\n\n<li><strong>Delivery System<\/strong>: LNP-mediated cellular delivery for intracellular protein expression<\/li>\n\n\n\n<li><strong>Antigen Presentation<\/strong>: E6\/E7 proteins presented via human leukocyte antigen (HLA) molecules<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-immunological-mechanism\" class=\"wp-block-heading\">Immunological Mechanism<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T-cell Induction<\/strong>: Generates E6- and E7-specific cytotoxic T lymphocytes<\/li>\n\n\n\n<li><strong>Targeted Elimination<\/strong>: Immune-mediated eradication of HPV-infected cells and precancerous lesions<\/li>\n\n\n\n<li><strong>Pathogenic Focus<\/strong>: Addresses HPV 16\/18, responsible for 70% of cervical cancer cases globally<\/li>\n\n\n\n<li><strong>Therapeutic Paradigm<\/strong>: Shifts from surgical ablation to immune-mediated clearance<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-innovation\" class=\"wp-block-heading\">Clinical Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-Surgical Approach<\/strong>: First-in-class alternative to loop electrosurgical excision procedure (LEEP) and cryotherapy<\/li>\n\n\n\n<li><strong>Precision Targeting<\/strong>: Specifically addresses molecular drivers of cervical carcinogenesis<\/li>\n\n\n\n<li><strong>Preventive Potential<\/strong>: May prevent progression to invasive cervical cancer through early intervention<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Addresses approximately 500,000-700,000 Chinese women annually diagnosed with HPV 16\/18-related HSIL<\/li>\n\n\n\n<li><strong>Current Standard of Care<\/strong>: Surgical procedures carry risks of cervical stenosis, bleeding, and impact on future fertility<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong>: Potential to capture significant share of $800 million Chinese cervical precancer treatment market<\/li>\n\n\n\n<li><strong>mRNA Platform Validation<\/strong>: Demonstrates CSPC&#8217;s capability in advanced nucleic acid therapeutics beyond traditional small molecules<\/li>\n\n\n\n<li><strong>Global Significance<\/strong>: Success could position China as leader in therapeutic mRNA vaccines for oncology applications<\/li>\n\n\n\n<li><strong>Healthcare Economics<\/strong>: Non-surgical approach may reduce procedural costs and complications while improving patient quality of life<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-context\" class=\"wp-block-heading\">Strategic Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The SYS 6026 development represents CSPC&#8217;s strategic diversification into cutting-edge biologics and mRNA therapeutics, leveraging lessons from the global pandemic-era mRNA platform advancements. Cervical HSIL represents an ideal indication for therapeutic vaccination due to well-defined viral etiology, accessible lesion location, and clear unmet need for fertility-preserving treatments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">HPV types 16 and 18 are the most oncogenic subtypes, with persistent infection leading to progressive dysplasia and eventual invasive carcinoma. Current management relies heavily on surgical intervention, creating substantial opportunity for immune-mediated therapeutic alternatives that preserve cervical anatomy and function.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072201162_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072201162_c.\"><\/object><a id=\"wp-block-file--media-2d0eb274-c5ea-4707-bd36-c69f7e8d4369\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072201162_c.pdf\">2026072201162_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072201162_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2d0eb274-c5ea-4707-bd36-c69f7e8d4369\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,171,855,12],"class_list":["post-70528","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial in China for SYS 6026 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL). The Class 1 therapeutic biological product represents China&#039;s first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70528\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial in China for SYS 6026 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL). The Class 1 therapeutic biological product represents China&#039;s first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70528\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T14:17:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T14:17:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70528#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70528\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer\",\"datePublished\":\"2026-07-23T14:17:21+00:00\",\"dateModified\":\"2026-07-23T14:17:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70528\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70528#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70528\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70528\",\"name\":\"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-23T14:17:21+00:00\",\"dateModified\":\"2026-07-23T14:17:23+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial in China for SYS 6026 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL). The Class 1 therapeutic biological product represents China's first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70528#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70528\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70528#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial in China for SYS 6026 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL). The Class 1 therapeutic biological product represents China's first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70528","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer","og_description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial in China for SYS 6026 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL). The Class 1 therapeutic biological product represents China's first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.","og_url":"https:\/\/flcube.com\/?p=70528","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-23T14:17:21+00:00","article_modified_time":"2026-07-23T14:17:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70528#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70528"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer","datePublished":"2026-07-23T14:17:21+00:00","dateModified":"2026-07-23T14:17:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70528"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70528#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70528","url":"https:\/\/flcube.com\/?p=70528","name":"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-23T14:17:21+00:00","dateModified":"2026-07-23T14:17:23+00:00","description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial in China for SYS 6026 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV) types 16 and 18-related cervical high-grade squamous intraepithelial lesion (HSIL). The Class 1 therapeutic biological product represents China's first mRNA-based therapeutic vaccine for precancerous cervical lesions, offering a potential non-surgical alternative to current ablative procedures.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70528#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70528"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70528#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70528"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70528\/revisions"}],"predecessor-version":[{"id":70530,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70528\/revisions\/70530"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}